Optina, a Montreal, Canada-based diagnostics company focused on retinal imaging, brain health and systemic disease detection, closed an up to US$2.1M funding round.
The Alzheimer’s Drug Discovery Foundation (ADDF) made the investment through the ADDF’s Diagnostics Accelerator, a collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others. This funding follows the closing of a Series-A round led by DigitalDx Ventures including Boehringer Ingelheim Venture Fund, Desjardins, Zoic Capital as well as other investors.
This new funding will support Optina’s pivotal study for the FDA regulatory submission of the awAIrTM cerebral amyloid status test for Alzheimer’s disease detection, aligning Optina’s platform with novel therapeutic approvals. Specifically, this new financing will enable the company to expand its pivotal study’s cohort size. The clinical study will take place across 5 sites in USA, Canada and Europe
Led by David Lapointe, CEO, Optina Diagnostics is advancing the Retinal Deep PhenotypingTM platform which obtained the FDA Breakthrough Device Designation status in 2019 for its first indication, a non-invasive and more accessible test to improve diagnosis accuracy and the management of patients undergoing evaluation for Alzheimer’s disease (AD) and received 501(k) clearance for its hyper-spectral Optina-4CTM camera in 2020.
FinSMEs
24/01/2022